Dlin-MC3-DMA: Benchmark Ionizable Cationic Liposome for Lipid Nanoparticle siRNA Delivery

Executive Summary: Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7) is an ionizable cationic lipid essential for efficient lipid nanoparticle (LNP) siRNA and mRNA delivery [APExBIO]. It enables high-potency hepatic gene silencing, with an ED₅₀ as low as 0.005 mg/kg in mice and 0.03 mg/kg in non-human primates (Wang et al., 2022). Its pH-dependent charge promotes endosomal escape and cytoplasmic delivery while minimizing toxicity at physiological pH. Machine learning and molecular modeling have validated its superior performance in mRNA vaccine LNPs (Wang et al., 2022). Dlin-MC3-DMA is a cornerstone in immunomodulatory and cancer immunochemotherapy applications [AH6809.com].

Biological Rationale

Lipid nanoparticles (LNPs) are the primary non-viral systems for delivering nucleic acids, such as siRNA and mRNA, into cells (Wang et al., 2022). Ionizable cationic lipids like Dlin-MC3-DMA are critical for LNP function due to their ability to bind nucleic acids via electrostatic interactions at acidic pH and release cargo in the cytoplasm. This pH-dependent behavior optimizes cellular uptake, endosomal escape, and reduces off-target effects and cytotoxicity [Q-VD.com]. Dlin-MC3-DMA's structure, featuring a tertiary amine, allows reversible protonation. This property is leveraged in advanced mRNA vaccine formulations and siRNA delivery vehicles for hepatic gene silencing and cancer immunotherapy [RilmenidineRx.com].

Mechanism of Action of Dlin-MC3-DMA (DLin-MC3-DMA, CAS No. 1224606-06-7)

Dlin-MC3-DMA is neutral at physiological pH (7.4), minimizing systemic toxicity. Upon cellular uptake, endosomal acidification (pH ~5–6) causes the tertiary amine to protonate, conferring a positive charge. This cationic state disrupts endosomal membranes via the 'proton sponge' effect, facilitating endosomal escape of the LNP cargo into the cytoplasm (Wang et al., 2022). The process enhances gene silencing efficiency for siRNA and robust translation for mRNA therapeutics. Dlin-MC3-DMA is formulated with helper lipids such as DSPC, cholesterol, and PEG-DMG, creating stable, reproducible LNPs. The molecular structure enables efficient encapsulation and protects nucleic acids from serum nucleases.

Evidence & Benchmarks

• Dlin-MC3-DMA-based LNPs achieved >1000-fold greater potency in hepatic gene silencing versus DLin-DMA, with ED₅₀ values of 0.005 mg/kg (mouse, Factor VII) and 0.03 mg/kg (non-human primate, TTR) (Wang et al., 2022, DOI).
• Machine learning models (LightGBM) trained on 325 mRNA LNP datasets identified Dlin-MC3-DMA as the highest efficacy ionizable lipid for mRNA vaccine delivery (Wang et al., 2022, DOI).
• LNPs with Dlin-MC3-DMA at an N/P ratio of 6:1 outperformed those with SM-102 in murine in vivo mRNA delivery (Wang et al., 2022, DOI).
• Dlin-MC3-DMA exhibits high solubility in ethanol (≥152.6 mg/mL) but is insoluble in water and DMSO, requiring careful formulation handling (APExBIO).
• Storage at −20°C or below is necessary to prevent degradation; solutions should be used immediately after preparation (APExBIO).

This article extends the mechanistic and benchmarking insights of "Dlin-MC3-DMA: Mechanistic Mastery and Strategic Foresight…" by providing atomic, experimental details and explicit workflow parameters for LNP formulation.

For practical scenario-driven guidance, our discussion clarifies and updates best practices outlined in "Optimizing Lipid Nanoparticle siRNA Delivery with Dlin-MC3-DMA" by focusing on quantitative performance and storage benchmarks.

Applications, Limits & Misconceptions

Dlin-MC3-DMA is central to:

• Lipid nanoparticle-mediated gene silencing, especially hepatic targets.
• mRNA vaccine formulation for infectious diseases and immunotherapies.
• Immunomodulatory and cancer immunochemotherapy research platforms.

Its high potency and low toxicity profile make it a preferred component for translational and clinical research. Dlin-MC3-DMA has been used as the ionizable lipid in the first FDA-approved siRNA-LNP drug, patisiran (for hereditary transthyretin-mediated amyloidosis) (Wang et al., 2022).

Common Pitfalls or Misconceptions

• Dlin-MC3-DMA is not water or DMSO soluble. Attempting aqueous stock solutions leads to phase separation and loss of activity.
• Not all ionizable lipids are interchangeable. Potency and toxicity profiles differ significantly; Dlin-MC3-DMA outperforms SM-102 and DLin-DMA in mRNA delivery, but each must be validated for specific applications (Wang et al., 2022).
• Storage conditions are critical. Repeated freeze-thaw cycles or storage above −20°C can degrade Dlin-MC3-DMA and compromise LNP integrity (APExBIO).
• Not universally applicable for all cell types. While highly effective for hepatic gene targeting, Dlin-MC3-DMA-based LNPs may require optimization for other tissues.
• Endosomal escape is not guaranteed in all contexts. Cellular uptake and intracellular trafficking can vary; efficiency should be empirically validated.

Workflow Integration & Parameters

For formulation, Dlin-MC3-DMA is typically combined with DSPC, cholesterol, and PEG-DMG in a molar ratio of 50:10:38.5:1.5, respectively (Wang et al., 2022). Ethanol is recommended as the solvent, with stock concentrations up to 152.6 mg/mL. LNP assembly is commonly performed by rapid mixing of lipid and aqueous nucleic acid phases using microfluidics or ethanol dilution methods at room temperature. The N/P (nitrogen to phosphate) ratio is typically set at 6:1 for maximal in vivo efficacy. Prepared LNPs should be buffer-exchanged into physiological saline for in vivo use. All solutions must be freshly prepared and used immediately to prevent degradation. For further troubleshooting and advanced protocols, refer to "Dlin-MC3-DMA: Ionizable Cationic Liposome for Next-Gen LNP Delivery", which discusses advanced use-cases and troubleshooting beyond this article's scope.

Conclusion & Outlook

Dlin-MC3-DMA from APExBIO remains the benchmark for ionizable cationic liposome use in lipid nanoparticle siRNA delivery and mRNA drug delivery lipid applications. Its validated potency, safety, and robust performance in both experimental and computational studies underpin its widespread adoption. Continued machine learning-guided optimization will further refine LNP formulations for precision medicine. For detailed product information or ordering, see the Dlin-MC3-DMA product page (A8791).